



SAFETY CHECKLIST FOR PRESCRIBING PHYSICIAN

Pirfenidone

This safety checklist contains key elements to follow when prescribing Pirfenidone:

Liver function

- Pirfenidone is contraindicated in patients with severe hepatic impairment or end stage liver disease.
- Elevations of serum transaminases can occur during treatment with Pirfenidone.
- There is a need to monitor liver function tests prior to initiation of treatment with Pirfenidone and at regular intervals thereafter.
- Close monitoring is required of any patients who develop liver enzyme elevation. Appropriate dose adjustment or discontinuation may be required.

Photosensitivity

- Patients should be informed that Pirfenidone is known to be associated with photosensitivity reactions and that preventative measures have to be taken.
- Patients are advised to avoid or reduce exposure to direct sunlight (including sunlamps).
- Patients should be instructed to use a sunblock daily, to wear clothing that protects against sun exposure, and to avoid other medications known to cause photosensitivity.

Before initiating Pirfenidone, and in addition to reading the Summary of Product Characteristics (SmPC), please check each of the following:

Indication for use

- I am satisfied that the patient is an adult with a diagnosis of idiopathic pulmonary fibrosis (IPF)
- I have started therapy at 267 mg three times a day and the patient has been advised that therapy will be titrated according to the recommendations of the Summary of Product Characteristics (SmPC)
- I have advised the patient to take Pirfenidone with food and to avoid grapefruit and grapefruit juice while they are being treated with Pirfenidone

Before starting Pirfenidone I have:

- Checked whether the patient is hypersensitive to Pirfenidone
- Checked whether the patient is on medication which could potentially interact adversely with Pirfenidone
- Arranged for adequate monitoring for abnormal liver function tests

This educational material is provided by Glenmark Pharmaceuticals Europe Limited and is mandatory as a condition of the Marketing Authorisation in order to further minimise important selected risks.

Date of preparation: April 2025
Version 2.0
MHRA approval date: June 2025

Drug-induced Liver Injury

Prior to initiation of treatment:

- The patient does not have severe hepatic impairment or end stage liver disease. Pirfenidone is contraindicated in patients with severe hepatic impairment or end stage liver disease
- Liver function tests have been performed prior to initiation of treatment with Pirfenidone
- I am aware that elevations of serum transaminases can occur during treatment with Pirfenidone
- The patient is informed that serious liver injury may occur and that he/she should contact their prescribing physician or regular physician immediately for clinical evaluation and liver function tests if symptoms of liver injury including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice (as described in the patient information leaflet) occur

During treatment:

- Liver function tests will be performed monthly in the first six months of treatment
- Liver function tests will be performed every three months thereafter during treatment
- Patients who develop liver enzyme elevations will be closely monitored and the dose of Pirfenidone will be adjusted or treatment will be permanently discontinued if necessary (please refer to the SmPC for recommendations)
- Prompt clinical evaluation and liver function tests will be performed if a patient develops symptoms or signs of liver injury (please refer to the SmPC for recommendations)

Photosensitivity

- The patient is informed that Pirfenidone is known to be associated with photosensitivity reactions and that preventive measures have to be taken
- The patient is advised to avoid or reduce exposure to direct sunlight (including sunlamps)
- The patient is instructed to use a sunblock daily, to wear clothing that protects against sun exposure, and to avoid other medications known to cause photosensitivity
- The patient is informed that he/she should report to the prescribing physician or regular physician if any new and significant skin rash occurs

Reporting of adverse events

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

If you are aware of any suspected adverse drug reactions (ADR) associated with the use of Pirfenidone, including clinically significant photosensitivity reactions and skin rashes, drug-induced liver injury, clinically significant abnormal liver function tests and any other clinically significant ADRs, please report such information.

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/> or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to Glenmark Pharmaceuticals Europe Ltd. Please contact Glenmark by emailing Medical_Information@glenmarkpharma.com or calling 0800 458 0383.

This educational material is provided by Glenmark Pharmaceuticals Europe Limited and is mandatory as a condition of the Marketing Authorisation in order to further minimise important selected risks.

Date of preparation: April 2025
Version 2.0
MHRA approval date: June 2025